Puma Biotechnology launches Phase II ALISCA-Lung2 trial of alisertib plus paclitaxel in advanced small cell lung cancer
PBYI•PBYI•PBYI•PBYI•The study targets about 50 previously treated patients, aiming to assess safety while gauging signals of anti-tumor activity.
Biomarker work is planned to identify patient subgroups most likely to benefit, supporting future development decisions for alisertib.
Puma Biotechnology launched ALISCA-Lung2, a Phase II study of alisertib with paclitaxel in advanced small cell lung cancer.
No trial results have been presented; readouts are expected in the future as enrollment progresses.
